Compare NVVEW & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NVVEW | IDYA |
|---|---|---|
| Founded | N/A | 2015 |
| Country | China | United States |
| Employees | 12 | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.9B |
| IPO Year | 2020 | 2019 |
| Metric | NVVEW | IDYA |
|---|---|---|
| Price | $0.02 | $33.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $49.18 |
| AVG Volume (30 Days) | N/A | ★ 904.3K |
| Earning Date | N/A | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $214,834,000.00 |
| Revenue This Year | N/A | $2,662.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5377.66 |
| 52 Week Low | N/A | $13.45 |
| 52 Week High | N/A | $37.08 |
| Indicator | NVVEW | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 47.93 | 47.74 |
| Support Level | $0.01 | $34.04 |
| Resistance Level | $0.02 | $35.28 |
| Average True Range (ATR) | 0.00 | 1.07 |
| MACD | 0.00 | -0.16 |
| Stochastic Oscillator | 52.24 | 22.76 |
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.